Central administration of melanocortin agonist increased insulin sensitivity in diet-induced obese rats.

Banno R, Arima H, Hayashi M, Goto M, Watanabe M, Sato I, Ozaki N, Nagasaki H, Ozaki N, Oiso Y

FEBS letters16 Feb 2007Cited by 22 (Europe PMC)

PMID17321524DOI10.1016/j.febslet.2007.02.019PepBankPUB-17321524

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, intracerebroventricular melanotan II decreased food intake over 10 days.
In plain wordsIn obese rats, melanotan II given into the brain reduced food intake over 10 days.
Peptide
Melanotan II
Outcome
DecreaseFood intake
Study
ratn: not reported in source
diet-induced obese rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intracerebroventricular · 10 daysAs given in this study (rat).
Source sentences
Summary
Although MTII treatment significantly decreased food intake and body weight for 10 days
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we examined the effects of intracerebroventricular administration of melanotan II (MTII), a melanocortin agonist, on insulin sensitivity in diet-induced obese (DIO) rats.
Report a problemFND-1732152401
02AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, intracerebroventricular melanotan II decreased body weight over 10 days.
In plain wordsIn obese rats, melanotan II given into the brain reduced body weight over 10 days.
Peptide
Melanotan II
Outcome
DecreaseBody weight
Study
ratn: not reported in source
diet-induced obese rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · intracerebroventricular · 10 daysAs given in this study (rat).
Source sentences
Summary
Although MTII treatment significantly decreased food intake and body weight for 10 days
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we examined the effects of intracerebroventricular administration of melanotan II (MTII), a melanocortin agonist, on insulin sensitivity in diet-induced obese (DIO) rats.
Report a problemFND-1732152402
03AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, body weight did not differ between melanotan II and pair-fed groups.
In plain wordsIn obese rats, melanotan II and pair-feeding gave the same body weight.
Peptide
Melanotan II
Outcome
No significant changeBody weight versus pair-fed group
Study
ratn: not reported in source
diet-induced obese rats
Comparator
Pair-fed
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · intracerebroventricular · 10 daysAs given in this study (rat).
Source sentences
Summary
Although MTII treatment significantly decreased food intake and body weight for 10 days, there was no significant difference in body weight between MTII and pair-fed groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we examined the effects of intracerebroventricular administration of melanotan II (MTII), a melanocortin agonist, on insulin sensitivity in diet-induced obese (DIO) rats.
Report a problemFND-1732152403
04AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, insulin sensitivity improved more with melanotan II than with pair-feeding.
In plain wordsIn obese rats, melanotan II improved insulin sensitivity more than pair-feeding did.
Peptide
Melanotan II
Outcome
IncreaseInsulin sensitivity by insulin tolerance test
Study
ratn: not reported in source
diet-induced obese rats
Comparator
Pair-fed
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
The insulin tolerance test showed that insulin sensitivity was significantly improved in the MTII group compared to the pair-fed group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we examined the effects of intracerebroventricular administration of melanotan II (MTII), a melanocortin agonist, on insulin sensitivity in diet-induced obese (DIO) rats.
Report a problemFND-1732152404
05AnimalAnimal study (in vivo)Mechanism
In diet-induced obese rats, melanotan II increased the number of small adipocytes in epididymal white adipose tissue.
In plain wordsIn obese rats, melanotan II increased the number of small fat cells in one fat depot.
Peptide
Melanotan II
Outcome
IncreaseSmall-sized adipocytes in epididymal WAT
Study
ratn: not reported in source
diet-induced obese rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
Furthermore, MTII treatment increased the number of small-sized adipocytes in epididymal white adipose tissues
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we examined the effects of intracerebroventricular administration of melanotan II (MTII), a melanocortin agonist, on insulin sensitivity in diet-induced obese (DIO) rats.
Report a problemFND-1732152405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.